| Value | ₹1,158 Cr |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹722.70
- Market cap
- ₹11,375 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.0×Sector 46.1×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other results update announcements
All →Vaibhav Global Results Update
Vaibhav Global reported H1 & Q2 FY27 results via press release, with Q2 revenue up 7.0% to ₹938.4 crore and EBITDA of ₹76.2 crore. The release covers platform migration effects and segment performance.
InfoBeans Technologies Results Update
InfoBeans Technologies reported Q2 and H1 FY27 results, with H1 revenue up 30% to ₹322.6 crore and PAT up 22% to ₹47.9 crore. Management highlighted growth momentum, new clients and EBITDA gains.
OnEMI Technology Solutions Results Update
Kissht reported Q2FY27 PAT of ₹125 Crore, doubling year-on-year, with AUM up 68% to ₹9,317 Crore. Press release accompanies unaudited Q2 and H1 FY27 results.
GMR Airports Results Update
GMR Airports reported Q2FY27 total income up 12% YoY to INR 4,188 Crs and PAT of INR 65 Crs. The filing is a press release accompanying the un-audited quarterly results.
MosChip Technologies Results Update
MosChip's Q2 FY27 press release showed revenue of ₹119.08 Crore and an EBITDA loss of ₹18.82 Crore. Cost escalations on a turnkey ASIC project drove weaker profit.
Zensar Technologies Results Update
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.